3 results
To evaluate the safety and tolerability of treatment with atogepant 60 mg once daily when administered over 156 weeks for the prevention of migraine in participants with Chronic Migraine (CM) or Episodic Migraine (EM).
To prospectively test for superiority of atogepant 60 mg QD versus placebo for the prevention of migraine in participants with episodic migraine who have previously failed 2 to 4 classes of oral medications for the prophylaxis of migraine
This clinical performance study will evaluate the effectiveness of the Ki 67 IHC MIB-1 pharmDx (Dako Omnis) to identify estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- early breast cancer patients whose tumours score Ki-67…